[{"from": "human", "value": "Provide a brief overview of this molecule. [C][C@H1][C][=Branch1][C][=O][N][C@H1][Branch2][Branch1][Branch1][C][=Branch1][C][=O][N][C@@H1][Branch2][Ring2][#Branch1][C][S][S][C][C@@H1][Branch2][Ring1][=Branch2][C][=Branch1][C][=O][N][C@H1][Branch1][=Branch2][C][=Branch1][C][=O][N][Ring2][Ring1][Branch1][C][C][=C][N][=C][N][Ring1][Branch1][N][C][=Branch1][C][=O][C][C][=Branch1][C][=O][N][C][Branch1][C][C][C]"}, {"from": "gpt", "value": "The molecule is a small, cyclic pentapeptide vascular-targeting agent with potential antineoplastic and antiangiogenic activities. ADH-1 selectively and competitively binds to and blocks N-cadherin, which may result in disruption of tumor vasculature, inhibition of tumor cell growth, and the induction of tumor cell and endothelial cell apoptosis. N-cadherin, a cell- surface transmembrane glycoprotein of the cadherin superfamily of proteins involved in calcium-mediated cell-cell adhesion and signaling mechanisms; may be upregulated in some aggressive tumors and the endothelial cells and pericytes of some tumor blood vessels."}]